Inovio Pharmaceuticals, Inc. (BMV:INO)
Mexico · Delayed Price · Currency is MXN | Market Cap | 1.89B +49.5% |
| Revenue (ttm) | n/a -70.0% |
| Net Income | -1.53B |
| EPS | -28.09 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 304 |
| Open | 25.50 |
| Previous Close | 25.50 |
| Day's Range | 25.50 - 25.50 |
| 52-Week Range | 20.00 - 57.00 |
| Beta | n/a |
| RSI | 40.84 |
| Earnings Date | May 13, 2026 |
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and i... [Read more]
Financial Performance
In 2025, Inovio Pharmaceuticals's revenue was $65,343, a decrease of -69.99% compared to the previous year's $217,756. Losses were -$84.95 million, -20.80% less than in 2024.
Financial numbers in USD Financial StatementsNews
Inovio: ApolloBio announces ‘positive’ results from Phase 3 trial of VGX-3100
Inovio (INO) announced that its partner for VGX-3100 in China, ApolloBio, announced positive topline results from its pivotal Phase 3 trial of VGX-3100, INOVIO’s investigational DNA immunotherapy bein...
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate ApolloBio's new clinical results further high...
Inovio Pharmaceuticals Transcript: AGM 2026
Directors and key proposals were approved, including auditor ratification and executive compensation. Strategic focus is on advancing INO-3107 toward FDA approval and commercialization, with financial discipline and partnerships supporting pipeline progress.
Inovio Pharmaceuticals Earnings Call Transcript: Q1 2026
INO-3107 remains on track for its October 2026 PDUFA date, with FDA review progressing and no new issues raised. Financially, cash runway extends into Q1 2027 after a $16M equity raise, and commercial plans are advancing for a differentiated launch in a largely untapped RRP market.
Inovio Pharmaceuticals Quarterly report: Q1 2026
Inovio Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 13, 2026.
Inovio Pharmaceuticals Earnings release: Q1 2026
Inovio Pharmaceuticals released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Inovio Pharmaceuticals Slides: Q1 2026
Inovio Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee ...
Inovio options imply 15.1% move in share price post-earnings
Pre-earnings options volume in Inovio (INO) is normal with calls leading puts 72:1. Implied volatility suggests the market is anticipating a move near 15.1%, or 21c, after results are released.
Options Volatility and Implied Earnings Moves Today, May 13, 2026
Today, several major companies are expected to report earnings: Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Microvision (MVIS), Toyota Motor (TM), Wix (WIX), Alibaba (BABA), Eos Energy Enterpr...
Hantavirus cases spark surge in pharma and biotech stocks — here's why
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
INOVIO to Participate in Upcoming Scientific Conferences
PLYMOUTH MEETING, Pa., May 8, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-relate...
INOVIO to Report First Quarter Financial Results on May 13, 2026
PLYMOUTH MEETING, Pa., May 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-relate...
Inovio Pharmaceuticals Proxy statement: Proxy filing
Inovio Pharmaceuticals filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
INOVIO Announces Pricing of $17.5 Million Public Offering
PLYMOUTH MEETING, Pa., April 2, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prote...
INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prote...
INOVIO to Participate in Upcoming Scientific Conference
PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...
Shareholders Sue Inovio Pharmaceuticals Over DNA Technology Claims
A class action lawsuit was filed against Inovio Pharmaceuticals ($INO) on February 6, 2026. Plaintiffs – shareholders – in the federal securities class action allege that they acquired Inovio stock…
Inovio Pharmaceuticals Slides: Corporate presentation
Inovio Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on March 23, 2026.
Inovio Pharmaceuticals Earnings Call Transcript: Q4 2025
BLA for INO-3107 accepted by FDA with a PDUFA date of October 30, 2026, though eligibility for Accelerated Approval is under review. Cash runway extends into Q4 2026, with commercial launch preparations and pipeline partnerships advancing.
Inovio Pharmaceuticals Earnings release: Q4 2025
Inovio Pharmaceuticals released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Inovio Pharmaceuticals Annual report: Q4 2025
Inovio Pharmaceuticals has published its Q4 2025 annual report on March 12, 2026.
Inovio Pharmaceuticals Slides: Q4 2025
Inovio Pharmaceuticals has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 12, 2026.
INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U...
Options Volatility and Implied Earnings Moves Today, March 12, 2026
Today, several major companies are expected to report earnings: Adobe (ADBE), Ballard Power Systems (BLDP), Dollar General (DG), Inovio Pharmaceuticals (INO), Lennar (LEN), Wheaton Precious Metals (WP...